Tipranks Press Release.
Featuring Serina Therapeutics’ CEO - Thursday, September 24, 202610M people in the world currently living with Parkinson’s diseasewith no major cl...
HUNTSVILLE, AL, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology enabling drug product candidates to treat neurological diseases and other indications, today announced that Steve Ledger, Chief Executive Officer, will present at the upcoming H.C. Wainwright 28th Annual Global Investment Conference. The Company will also attend o
- Independent Safety Monitoring Committee recommends advancement to Cohort 2 following blinded review of Cohort 1 safety and tolerability data – - Pharmacokinetic observations at the lowest dose evaluated were consistent with the sustained apomorphine exposure SER-252 is designed to provide – - Blinded Cohort 1 observations included sustained periods of improvement in motor function in individual patients on exploratory clinical measures – - Serina expects to report topline data from the single-
Detailed price information for Serina Therapeutics Inc (SER-A) from The Globe and Mail including charting and trades.
Detailed price information for GE Healthcare Technologies (GEHC-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.